Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system

Brain Insulin Controls Adipose Tissue Lipolysis and Lipogenesis

(2011) Thomas Scherer et al.   Cell Metabolism

Molecular Characterization of Insulin-Mediated Suppression of Hepatic Glucose Production In Vivo

(2010) C. J. Ramnanan et al.   DIABETES

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes

(2010) Z. Wang et al.   DIABETES CARE

Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

(2010) A. R. Sørensen et al.   DIABETES OBESITY & METABOLISM

Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans

(2010) L. P. Sørensen et al.   DIABETIC MEDICINE

Pharmacodynamics of Insulin Detemir and Insulin Glargine Assessed by an Isoglycemic Clamp Method in Healthy Cats

(2010) C. Gilor et al.   JOURNAL OF VETERINARY INTERNAL MEDICINE

Insulin detemir is not transported across the blood–brain barrier

(2010) William A. Banks et al.   PEPTIDES

Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes

(2009) F. Smeeton et al.   DIABETOLOGIA

SirT1 knockdown in liver decreases basal hepatic glucose production and increases hepatic insulin responsiveness in diabetic rats

(2009) D. M. Erion et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis

(2008) M. Monami et al.   DIABETES OBESITY & METABOLISM